Heimbrger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
We cannot promise a specific number, because individual results vary widely based on starting weight, adherence, dose tolerance, and lifestyle factors
The risk profile for both is very similar, with the most common complaints being gastrointestinal (GI) symptoms
Ozempic (Semaglutide) Specific Risks Ozempic, or semaglutide, is used to manage type 2 diabetes
Current evidence shows no dementia risk, and maintaining good diabetes control with Ozempic may actually protect cognitive health by addressing underlying metabolic dysfunction